GLAUKOS Corp — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Glaukos reported Q2 2026 net sales of $185.6 million, up 50% reported (49% constant currency) versus Q2 2025's $124.1 million. U.S. Glaucoma sales reached $118.5 million (+64% YoY), with iDose TR contributing ~$74 million. Corneal Health sales were $30.4 million (+48% YoY), including Epioxa's ~$11 million debut contribution. The company raised full-year 2026 guidance from $620–635 million to $680–700 million. Gross margin improved 150 basis points to ~85% non-GAAP. The company ended Q2 with $289.3 million in cash and no debt.
Why this rating
Strong revenue growth (+50% YoY) significantly exceeds typical pharma/medtech; major guidance raise (+9.7% midpoint) driven by two new products (iDose TR, Epioxa) gaining traction. At $5.9B market cap, ~$185.6M quarterly sales (~3.1% of cap annualized) reflects meaningful scale-up. However, still unprofitable; execution risks remain on reimbursement/MAC approvals. Significant but not transformational at this company stage.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.